The fusion landscape of hepatocellular carcinoma

doi:10.1002/1878-0261.12479

	The fusion landscape of hepatocellular carcinoma
	Zhu, Chengpei 1,2; Wu, Liangcai 1,2; Lv, Yanling 1,2,3; Guan, Jinxia 1,2,3; Bai, Xue 1,2; Lin, Jianzhen 1,2; Liu, Tingting 3; Yang, Xiaobo 1,2; Robson, Simon C.4,5; Sang, Xinting 1,2
刊名	MOLECULAR ONCOLOGY
	2019-05-01
卷号	13 期号:5 页码:1214-1225
关键词	biomarker gene fusion hepatocellular carcinoma recurrent fusion gene
ISSN号	1574-7891
DOI	10.1002/1878-0261.12479
通讯作者	Sang, Xinting(SangXT@pumch.cn) ; Xue, Chenghai(chenghai.xue@myhealthgene.com) ; Zhao, Haitao(ZhaoHT@pumch.cn)
英文摘要	Most cases of hepatocellular carcinoma (HCC) are already advanced at the time of diagnosis, which limits treatment options. Challenges in early-stage diagnosis may be due to the genetic complexity of HCC. Gene fusion plays a critical function in tumorigenesis and cancer progression in multiple cancers, yet the identities of fusion genes as potential diagnostic markers in HCC have not been investigated. Here, we employed STAR-Fusion and identified 43 recurrent fusion events in our own and four public RNA-seq datasets. We identified 2354 different gene fusions in two hepatitis B virus (HBV)-HCC patients. Validation analysis against the four RNA-seq datasets revealed that only 1.8% (43/2354) were recurrent fusions. Comparison with the four fusion databases demonstrated that 19 recurrent fusions were not previously annotated to diseases and three were annotated as disease-related fusion events. Finally, we validated six of the novel fusion events, including RP11-476K15.1-CTD-2015H3.2, by RT-PCR and Sanger sequencing of 14 pairs of HBV-related HCC samples. In summary, our study provides new insights into gene fusions in HCC and may contribute to the development of anti-HCC therapy.
资助项目	International Science and Technology Cooperation Projects[2016YFE0107100] ; International Science and Technology Cooperation Projects[2015DFA30650] ; CAMS Innovation Fund for Medical Science (CIFMS)[2017-I2M-4-003] ; Capital Special Research Project for Health Development[2014-2-4012] ; Beijing Natural Science Foundation[L172055] ; National Ten-thousand Talent Program ; Beijing Science and Technology Cooperation Special Award Subsidy Project
WOS关键词	GENE FUSIONS ; RNA-SEQ ; CHIMERIC TRANSCRIPT ; IMATINIB MESYLATE ; CANCER ; IDENTIFICATION ; TRANSLOCATIONS ; HETEROGENEITY ; CHROMOSOME ; BIOMARKERS
WOS研究方向	Oncology
语种	英语
出版者	WILEY
WOS记录号	WOS:000477090700016
资助机构	International Science and Technology Cooperation Projects ; CAMS Innovation Fund for Medical Science (CIFMS) ; Capital Special Research Project for Health Development ; Beijing Natural Science Foundation ; National Ten-thousand Talent Program ; Beijing Science and Technology Cooperation Special Award Subsidy Project
内容类型	期刊论文
源URL	[http://ir.ia.ac.cn/handle/173211/27787]
专题	中国科学院自动化研究所
通讯作者	Sang, Xinting; Xue, Chenghai; Zhao, Haitao
作者单位	1.Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Liver Surg, Beijing 100730, Peoples R China 2.Peking Union Med Coll, Beijing 100730, Peoples R China 3.My Hlth Gene Technol Co Ltd, Serv Ctr Tianjin Chentang Sci & Technol Commercia, Tianjin, Peoples R China 4.Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Ctr Liver, Boston, MA 02115 USA 5.Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Transplant Inst, Boston, MA 02115 USA 6.Chinese Acad Sci, Inst Automat, Joint Lab Large Scale Med Data Pattern Min & Appl, Beijing, Peoples R China
推荐引用方式 GB/T 7714	Zhu, Chengpei,Wu, Liangcai,Lv, Yanling,et al. The fusion landscape of hepatocellular carcinoma[J]. MOLECULAR ONCOLOGY,2019,13(5):1214-1225.
APA	Zhu, Chengpei.,Wu, Liangcai.,Lv, Yanling.,Guan, Jinxia.,Bai, Xue.,...&Zhao, Haitao.(2019).The fusion landscape of hepatocellular carcinoma.MOLECULAR ONCOLOGY,13(5),1214-1225.
MLA	Zhu, Chengpei,et al."The fusion landscape of hepatocellular carcinoma".MOLECULAR ONCOLOGY 13.5(2019):1214-1225.